Indian Pharmaceuticals Become Suit Filers Rather Than Those Being Sued (India)
This article was originally published in PharmAsia News
Now that Indian generic pharmaceutical companies are developing and marketing their own drugs, their patent role is beginning to switch from being sued to filing the suits. About 40 percent of the 8,000 drug patents filed in India between 1995 and 2004 were by Indian drug makers. A university professor says many of those patent applications are considered frivolous, claiming new laboratory techniques even though they do not qualify for patents. But he noted the pipeline of discovery drugs is drying up while companies seek another patent for a drug after changing its makeup a bit. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.